Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 207127 + faldaprevir + ribavirin in treatment-naive genotype 1b chronic hepatitis C
NL-OMON40119Phase 3Active, not recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Feb 2013
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of deleobuvir, faldaprevir and ribavirin in chronic hepatitis C (CHC) (4 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Clinically meaningful difference between 16-week and 24-week treatment durations. Started Feb 2013; status: active, not recruiting.
02
Drugs
deleobuvirfaldaprevirribavirin
03
Conditions
chronic hepatitis C (CHC)
Beyond the preview
Go deeper on NL-OMON40119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40119.